- Breast cancer
-
Upregulated N6-Methyladenosine RNA in Peripheral Blood: Potential Diagnostic Biomarker for Breast Cancer
-
Han Xiao, Xiaobo Fan, Rui Zhang, Guoqiu Wu
-
Cancer Res Treat. 2021;53(2):399-408. Published online October 27, 2020
-
DOI: https://doi.org/10.4143/crt.2020.870
-
-
 Abstract
 PDF Supplementary Material PubReader ePub
- Purpose
An effective biomarker for the diagnosis of breast cancer (BC) and benign breast diseases (BBD) is crucial for improving the prognosis. We investigated whether N6-methyladenosine (m6A) can be a diagnostic biomarker of BC.
Materials and Methods
We detected the contents of peripheral blood m6A in 62 patients with BC, 41 patients with BBD, and 41 normal controls (NCs) using the colorimetric method. The relative expression of the m6A regulated genes methyltransferase-like 14 (METTL14) and fat mass and obesity-associated (FTO) was analyzed using quantitative real-time polymerase chain reaction.
Results
m6A in peripheral blood RNA was significantly higher in patients with BC than that in patients with BBD (p < 0.001) or the NCs (p < 0.001). m6A was closely associated with the disease stage (from stage 0 to stage I-IV, p=0.003). The receiver operating characteristic curve of m6A contained an area under the curve (AUC) value of 0.887 in BC, which was greater than that of carcinoembryonic antigen (CEA) or carbohydrate antigen 153 (CA153). The combination of m6A, CEA, and CA153 improved the AUC to 0.914. The upregulated and downregulated mRNA expression of METTL14 and FTO, respectively, might contribute to the increase of m6A in patients with BC. m6A combined with METTL14 and FTO improved the AUC to 0.929 with a specificity of 97.4% in the peripheral blood of patients with BC.
Conclusion
The peripheral blood RNA of m6A might be a valuable biomarker for the diagnosis of BC.
-
Citations
Citations to this article as recorded by  - Demethylase FTO inhibits the occurrence and development of triple-negative breast cancer by blocking m<sup>6</sup>A-dependent miR-17-5p maturation-induced ZBTB4 depletion
Jingyi Ni, Xiaoyun Lu, Xiangxiang Gao, Conghui Jin, Junfeng Mao
Acta Biochimica et Biophysica Sinica.2024; 56(1): 114. CrossRef - Unraveling the cross‐talk between N6‐methyladenosine modification and non‐coding RNAs in breast cancer: Mechanisms and clinical implications
Xuan Liu, Xuelong Xie, Chentao Sui, Xuexue Liu, Miao Song, Qing Luo, Ping Zhan, Jia Feng, Jinbo Liu
International Journal of Cancer.2024; 154(11): 1877. CrossRef - N6-methyladenosine levels in peripheral blood RNA: a potential diagnostic biomarker for colorectal cancer
Chunying Zhang, Jiadi Chen, Jingyi Ren, Xiaoyu Li, Yaqin Zhang, Bihan Huang, Yihan Xu, Luyan Dong, Yingping Cao
Cancer Cell International.2024;[Epub] CrossRef - Demethylases in tumors and the tumor microenvironment: Key modifiers of N6-methyladenosine methylation
Junchen Guo, Liang Zhao, Meiqi Duan, Zhi Yang, He Zhao, Baiming Liu, Yihan Wang, Liping Deng, Chen Wang, Xiaodi Jiang, Xiaofeng Jiang
Biomedicine & Pharmacotherapy.2024; 174: 116479. CrossRef - The interaction between m6A modification and noncoding RNA in tumor microenvironment on cancer progression
Liushan Wei, Shun Liu, Zhizhong Xie, Guotao Tang, Xiaoyong Lei, Xiaoyan Yang
International Immunopharmacology.2024; 140: 112824. CrossRef - Simultaneous detection of membrane protein and mRNA at single extracellular vesicle level by droplet microfluidics for cancer diagnosis
Huixian Lin, Bo Li, Jingyun Guo, Xueying Mai, Haiyang Yu, Weilun Pan, Bodeng Wu, Wei Liu, Mingzhen Zhong, Tong Liao, Ye Zhang, Bo Situ, Xiaohui Yan, Yifan Liu, Chunchen Liu, Lei Zheng
Journal of Advanced Research.2024;[Epub] CrossRef - METTL protein family: focusing on the occurrence, progression and treatment of cancer
Huhu Zhang, Fulin Sun, Shuyao Jiang, Fanghao Yang, Xiaolei Dong, Guoxiang Liu, Mengjun Wang, Ya Li, Mohan Su, Ziyuan Wen, Chunjuan Yu, Chenkai Fan, Xiaoxia Li, Zhe Zhang, Lina Yang, Bing Li
Biomarker Research.2024;[Epub] CrossRef - Multiomics analyses and machine learning of nuclear receptor coactivator 6 reveal its essential role in hepatocellular carcinoma
Yinghao Fang, Yuyan Xu, Wei Liao, Tao Ji, Linyuan Yu, Longhai Li, Mingxin Pan, Dinghua Yang
Cancer Science.2023; 114(1): 75. CrossRef - Effect of Polyphenols and Zinc Co-Supplementation on the Development of Neoplasms in Rats with Breast Cancer
Martyna Jastrzębska, Joanna Giebułtowicz, Andrzej K. Ciechanowicz, Robert Wrzesień, Wojciech Bielecki, Barbara Bobrowska-Korczak
Foods.2023; 12(2): 356. CrossRef - Understanding the Epitranscriptome for Avant-Garde Brain Tumour Diagnostics
Ágota Tűzesi, Susannah Hallal, Laveniya Satgunaseelan, Michael E. Buckland, Kimberley L. Alexander
Cancers.2023; 15(4): 1232. CrossRef - Development of a N6-methyladenosine-directed single quantum dot-based biosensor for sensitive detection of METTL3/14 complex activity in breast cancer tissues
Ming-hao Liu, Wan-tong Yu, Ning-ning Zhao, Jian-Ge Qiu, Bing-Hua Jiang, Yan Zhang, Chun-yang Zhang
Analytica Chimica Acta.2023; 1279: 341796. CrossRef - Functions, mechanisms, and therapeutic implications of METTL14 in human cancer
Qian Guan, Huiran Lin, Lei Miao, Huiqin Guo, Yongping Chen, Zhenjian Zhuo, Jing He
Journal of Hematology & Oncology.2022;[Epub] CrossRef - Methyladenosine Modification in RNAs: From Regulatory Roles to Therapeutic Implications in Cancer
Xiaolin Qu, Yongqiu Zhang, Xianzheng Sang, Ding Ren, Hong Zhao, Stephen T. C. Wong
Cancers.2022; 14(13): 3195. CrossRef - METTL14 promotes migration and invasion of choroidal melanoma by targeting RUNX2 mRNA via m6A modification
Xi Zhang, Xiaonan Zhang, Tengyue Liu, Zhe Zhang, Chiyuan Piao, Hong Ning
Journal of Cellular and Molecular Medicine.2022; 26(22): 5602. CrossRef - Regulatory Role of N6-methyladenosine (m6A) Modification in Osteosarcoma
Yujie Zhang, Yanyan Wang, Liwei Ying, Sifeng Tao, Mingmin Shi, Peng Lin, Yangxin Wang, Bin Han
Frontiers in Oncology.2021;[Epub] CrossRef - Epitranscriptomics of Ischemic Heart Disease—The IHD-EPITRAN Study Design and Objectives
Vilbert Sikorski, Pasi Karjalainen, Daria Blokhina, Kati Oksaharju, Jahangir Khan, Shintaro Katayama, Helena Rajala, Satu Suihko, Suvi Tuohinen, Kari Teittinen, Annu Nummi, Antti Nykänen, Arda Eskin, Christoffer Stark, Fausto Biancari, Jan Kiss, Jarmo Sim
International Journal of Molecular Sciences.2021; 22(12): 6630. CrossRef - Regulatory roles of RNA modifications in breast cancer
Kanchan Kumari, Paula Groza, Francesca Aguilo
NAR Cancer.2021;[Epub] CrossRef - m6A target microRNAs in serum for cancer detection
Bo Zhang, Zhenmei Chen, Baorui Tao, Chenhe Yi, Zhifei Lin, Yitong Li, Weiqing Shao, Jing Lin, Jinhong Chen
Molecular Cancer.2021;[Epub] CrossRef
-
6,267
View
-
215
Download
-
20
Web of Science
-
18
Crossref
- Pediatric cancer
-
Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis
-
Ying Yang, Dong Wang, Lei Cui, Hong-Hao Ma, Li Zhang, Hong-Yun Lian, Qing Zhang, Xiao-Xi Zhao, Li-Ping Zhang, Yun-Ze Zhao, Na Li, Tian-You Wang, Zhi-Gang Li, Rui Zhang
-
Cancer Res Treat. 2021;53(1):261-269. Published online September 15, 2020
-
DOI: https://doi.org/10.4143/crt.2020.769
-
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Purpose
We sought to investigate the effectiveness and safety of dabrafenib in children with BRAFV600E-mutated Langerhans cell histiocytosis (LCH).
Materials and Methods
A retrospective analysis was performed on 20 children with BRAFV600E-mutated LCH who were treated with dabrafenib.
Results
The median age at which the patients started taking dabrafenib was 2.3 years old (range, 0.6 to 6.5 years). The ratio of boys to girls was 2.3:1. The median follow-up time was 30.8 months (range, 18.9 to 43.6 months). There were 14 patients (70%) in the risk organ (RO)+ group and six patients (30%) in the RO– group. All patients were initially treated with traditional chemotherapy and then shifted to targeted therapy due to poor control of LCH or intolerance to chemotherapy. The overall objective response rate and the overall disease control rate were 65% and 75%, respectively. During treatment, circulating levels of cell-free BRAFV600E (cfBRAFV600E) became negative in 60% of the patients within a median period of 3.0 months (range, 1.0 to 9.0 months). Grade 2 or 3 adverse effects occurred in five patients.
Conclusion
Some children with BRAFV600E-mutated LCH may benefit from monotherapy with dabrafenib, especially high-risk patients with concomitant hemophagocytic lymphohistiocytosis and intolerance to chemotherapy. The safety of dabrafenib is notable. A prospective study with a larger sample size is required to determine the optimal dosage and treatment duration.
-
Citations
Citations to this article as recorded by
-
34,687
View
-
229
Download
-
18
Web of Science
-
23
Crossref
|
KCA
